对于MASH治疗的FXR激动剂:从obeticholic酸的教训和观点
Kang Wang1, Yuecan Zhang1, Guangji Wang1
1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Medicinal research reviews
|October 30, 2023
概括
像肥酸这样的Farnesoid X受体 (FXR) 激动剂在治疗代谢功能障碍相关的脂肪肝炎 (MASH) 中表现有前途. 然而,适度的益处和安全问题需要进一步研究,以获得有效的MASH药物治疗.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 非酒精性脂肪性肝病 (NAFLD),现在是代谢功能障碍相关的脂肪性肝病 (MASLD),是一个缺乏批准治疗的全球健康问题.
- 法内索伊德X受体 (FXR) 激素因其代谢,抗炎症,抗亡和抗纤维性质而被研究用于MASLD/代谢功能障碍相关的脂肪肝炎 (MASH).
研究的目的:
- 审查OCA的发展,一个开创性的FXR激活剂,用于MASH治疗.
- 分析OCA的局限性,包括有效性和安全性问题,并为未来基于FXR的药物开发提供前景.
主要方法:
- 对MASH的OCA临床试验数据和科学文献的审查.
- 对OCA的作用机制,治疗效益和不良事件的分析.
主要成果:
- 在MASH临床试验中,OCA表现出适度的益处,但没有获得监管部门的批准.
- 与OCA相关的不良事件包括脂质不良,,胆病和潜在的肝毒性.
结论:
- 尽管OCA是一个领先者,但OCA的局限性凸显了基于FXR的MASH药疗中的挑战.
- 进一步的研究和开发至关重要,以克服安全性和有效性的障碍,以获得成功的FXR向MASH治疗.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
214
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
214
Drugs for Treatment of Diarrhea-Predominant IBS
186
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
186
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Drugs for Treatment of Constipation-Predominant IBS
181
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
181
Agonism and Antagonism: Quantification
383
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
383


